Metabolic Disorders
Page 1 • 2 itemsUnlock global pharma market insights on metabolic disorders. Stay ahead with critical regulatory, R&D, and investment intelligence for BD and analysts.
Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease
Opella's Essentiale essential phospholipids demonstrated 2.5 times greater liver fat reduction vs diet/exercise alone in MASLD patients in EXCEL trial.
EMA Recommends Approval of Plozasiran (Redemplo) for Rare Triglyceride Disorder FCS
European Medicines Agency recommends plozasiran (Redemplo) for marketing authorization to treat adults with familial chylomicronaemia syndrome in EU.